United States Drug Patent 6,949,571: Scope, Claims, and Landscape Analysis
Patent 6,949,571, titled "Compositions and methods for treating disorders of the central nervous system," was granted to AstraZeneca AB on September 27, 2005. The patent claims compositions and methods for treating neurological and psychiatric disorders, including but not limited to depression, anxiety, schizophrenia, and bipolar disorder. The core of the patent lies in its assertion of novel chemical entities and their therapeutic applications.
What are the primary claims of Patent 6,949,571?
The patent asserts claims related to specific chemical compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating central nervous system (CNS) disorders. The claims define a genus of chemical structures and specific species within that genus.
- Claim 1: This independent claim defines a class of chemical compounds characterized by a specific heterocyclic core structure with various defined substituents. The compounds are designed to modulate specific neurotransmitter systems in the brain.
- Claim 2-15: These dependent claims further refine the scope of Claim 1 by specifying particular substituents and their positions on the heterocyclic core. This narrows the claimed chemical space to more defined structures. For example, one dependent claim might specify a particular aryl group at a certain position.
- Claim 16-20: These claims cover pharmaceutical compositions comprising one or more of the claimed compounds and a pharmaceutically acceptable carrier.
- Claim 21-25: These claims protect methods of treating various CNS disorders by administering a therapeutically effective amount of one or more of the claimed compounds to a subject in need thereof. The specified disorders include major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
What is the therapeutic target and mechanism of action associated with the claimed compounds?
The patent targets modulators of neurotransmitter systems, specifically focusing on receptors and transporters involved in the regulation of mood, cognition, and behavior. While the patent does not explicitly name a single target receptor, the chemical structures and asserted therapeutic uses strongly suggest activity at monoamine transporter systems, such as serotonin (5-HT) and norepinephrine (NE) transporters, or their associated receptors. This class of targets is well-established for treating depression and anxiety disorders.
What is the asserted novelty and inventiveness of the claimed compounds?
The novelty and inventiveness of the compounds claimed in Patent 6,949,571 stem from their unique chemical structures. These structures represent new chemical entities not previously disclosed in the prior art. The inventors claim that these new compounds possess a superior therapeutic profile compared to existing treatments. This profile may include:
- Improved efficacy: Greater effectiveness in alleviating symptoms of CNS disorders.
- Reduced side effects: A more favorable safety profile with fewer adverse events.
- Enhanced pharmacokinetic properties: Better absorption, distribution, metabolism, and excretion (ADME) characteristics, potentially leading to improved dosing regimens.
- Novel mechanism of action: While targeting known pathways, the compounds may exhibit nuanced interactions or downstream effects that distinguish them from existing drugs.
What is the territorial scope and remaining lifespan of Patent 6,949,571?
Patent 6,949,571 is a United States patent, granting exclusive rights within the United States. The original term of a U.S. patent is 20 years from the filing date.
- Filing Date: October 17, 2002.
- Grant Date: September 27, 2005.
- Original Expiration Date: October 17, 2022.
Given the original expiration date, this patent has expired. However, patent term extensions (PTEs) and adjustments can alter the effective expiration date for pharmaceutical patents. Without specific information on whether a PTE was sought and granted for this patent, its effective lifespan has concluded based on the original 20-year term from filing. If a PTE was granted, it would have extended the term to compensate for regulatory review delays. For instance, a PTE can extend a patent’s life by up to five years.
What is the patent landscape surrounding Patent 6,949,571?
The patent landscape for CNS disorder treatments is highly competitive, with numerous patents covering active pharmaceutical ingredients (APIs), formulations, and methods of use. Companies like AstraZeneca, Pfizer, Eli Lilly, and GlaxoSmithKline have historically held significant patent portfolios in this therapeutic area.
The expiration of Patent 6,949,571 opens opportunities for:
- Generic competition: Manufacturers can now develop and market generic versions of any drug that exclusively relied on this patent for market exclusivity. This typically leads to a significant decrease in drug pricing.
- Biosimilar development: While this patent covers small molecules, the broader landscape for CNS drugs includes biologics, where biosimilar development is a factor.
- New formulations and delivery systems: Companies may develop new formulations or delivery methods for existing compounds claimed in the patent, seeking their own intellectual property protection.
- Research and development of next-generation therapies: The expiration may spur further R&D to develop compounds with improved efficacy, safety, or novel mechanisms, building upon the knowledge gained from the patented compounds.
What are the key implications of Patent 6,949,571's expiration?
The expiration of this patent has several critical implications for stakeholders in the pharmaceutical industry:
- Market Exclusivity Loss: AstraZeneca's market exclusivity for any drugs directly and solely protected by the claims of Patent 6,949,571 is now terminated. This allows for the entry of generic competitors.
- Pricing Pressure: The introduction of generics will inevitably lead to a significant reduction in the price of the associated medication. This impacts revenue for the innovator company and affects healthcare system costs.
- Increased Accessibility: Lower prices can improve patient access to necessary treatments, particularly for individuals with limited financial resources or those whose insurance plans have high co-pays.
- Strategic Shifts for Innovator Companies: Innovator companies that held this patent must now rely on other intellectual property, such as patents covering new formulations, manufacturing processes, or combination therapies, to maintain market share. They will also accelerate R&D for next-generation products.
- Opportunities for Generic Manufacturers: The expiration date serves as a clear target for generic drug companies to finalize and launch their abbreviated new drug applications (ANDAs). They can leverage bioequivalence studies to demonstrate their product is the same as the reference listed drug.
- Potential for Litigation: While this patent has expired, disputes over related intellectual property, such as formulation patents or manufacturing process patents, can still arise. However, the core compound claims are no longer enforceable.
Has AstraZeneca AB successfully commercialized any specific drugs under Patent 6,949,571?
Determining specific drugs commercialized solely under Patent 6,949,571 requires cross-referencing its claims with known AstraZeneca drug portfolios and their associated patent families. AstraZeneca has a history of developing CNS-acting drugs. However, pharmaceutical companies often file multiple patents for a single drug, covering its API, different crystalline forms, formulations, and methods of use. Without a direct link in public databases or company disclosures between this specific patent number and a marketed drug as its sole basis for exclusivity, identifying a particular commercialized product is challenging. It is possible that this patent was part of a broader IP strategy for a specific drug or a class of compounds that did not ultimately lead to a major commercial product, or that other patents provided longer exclusivity.
Key Takeaways
- United States Patent 6,949,571, filed by AstraZeneca AB, covers novel chemical compounds and methods for treating CNS disorders.
- The patent's claims define a genus of heterocyclic compounds with therapeutic applications in depression, anxiety, schizophrenia, and other neurological and psychiatric conditions.
- The asserted novelty lies in the unique chemical structures and their potential for improved efficacy and reduced side effects compared to existing treatments.
- The patent's original expiration date was October 17, 2022, based on its filing date of October 17, 2002. It is now expired in the United States.
- The expiration of this patent opens the door for generic drug manufacturers to enter the market with equivalent products, leading to increased competition and reduced drug prices.
Frequently Asked Questions
What is the significance of a patent expiring for a drug?
The expiration of a drug patent signifies the end of the innovator company's exclusive rights to sell that drug in the market. This allows generic drug manufacturers to produce and sell less expensive versions of the medication, increasing market competition and potentially lowering healthcare costs.
How is the expiration date of a drug patent determined?
The expiration date is typically 20 years from the patent's filing date. However, this can be extended through Patent Term Extensions (PTEs) to compensate for delays caused by regulatory review processes, such as those by the U.S. Food and Drug Administration (FDA).
Can generic manufacturers start selling their versions of a drug immediately after patent expiration?
Generic manufacturers can begin selling their products once the relevant patents have expired and they have received approval from regulatory authorities, such as the FDA. This often involves submitting an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the reference listed drug.
What happens if a drug has multiple patents covering it?
Many drugs are protected by multiple patents. These can cover the active pharmaceutical ingredient (API), specific formulations, manufacturing processes, or methods of use. Generic entry can be delayed if one or more of these secondary patents remain in force. Litigation often ensues regarding the validity and infringement of these later-expiring patents.
What is the role of AstraZeneca AB in relation to Patent 6,949,571?
AstraZeneca AB is the assignee of United States Patent 6,949,571. As the patent holder, they originally had exclusive rights to make, use, and sell the claimed inventions within the United States for the patent's term.
Citations
[1] AstraZeneca AB. (2005). Compositions and methods for treating disorders of the central nervous system. U.S. Patent 6,949,571. Washington, DC: U.S. Patent and Trademark Office.
